Johnson & Johnson announced that it has officially acquired Alios BioPharma for $1.7 billion in cash.
The acquisition will come with Alios’ portfolio of potential therapeutics for viral infections, including AL-8176, an orally administered antiviral therapy currently in Phase 2 studies for the treatment of respiratory syncytial virus.
The closing of the deal is subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act, but it is projected to close by the end of the fourth quarter of 2014.
For further deal information visit Current Agreements (subscription required)
Read: more on M&A deals in pharma, biotech, life science partnering deal news, insights and glossary
Report: Pharma and Biotech M&A Trends 2009-2014
View: M&A Scorecard in CP Insight– view top life science partnering deals by value
View: DealMetrics in CP Insight – the latest deal trend infographics for life science deal making
View: CP Insight’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: CP Insight’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity